ZORYVE® (roflumilast) topical foam, 0.3% | Patient Website
ZORYVE (rhymes with “BELIEVE”) is a once-daily, steroid-free, leave-in topical foam to treat seborrheic dermatitis and symptoms like flaking, redness, and itching.
Zoryve: Uses, Dosage, Side Effects & Warnings - Drugs.com
Oct 8, 2025 · Zoryve foam is a once-daily, steroid-free topical treatment that can be used anywhere on the body, including hairy areas. Zoryve foam for seborrheic dermatitis in patients …
ZORYVE (roflumilast) topical foam 0.3% | Official HCP Website
ZORYVE is an easy, once-daily, steroid-free topical foam designed to simplify seborrheic dermatitis control. See Safety and Product Info.
FAQ – Zoryve (roflumilast foam 0.3% or cream 0.15%)
Zoryve foam 0.3% is a once-daily topical, selective PDE4 inhibitor, which is indicated for the treatment of seborrheic dermatitis in individuals 9 years of age and older. The steroid-free …
ZORYVE® (roflumilast) topical foam, 0.3% - Arcutis Biotherapeutics
Learn more about ZORYVE (roflumilast) foam, a topical treatment for seborrheic dermatitis from Arcutis Biotherapeutics.
Roflumilast (ZORYVE) Foam in Seborrheic Dermatitis National Drug Monograph September 2024 VA Pharmacy Benefits Management Services and National Formulary Committee The …
ZORYVE foam, 0.3%, is a phosphodiesterase 4 inhibitor indicated for the treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older. (1)
Zoryve Topical Foam (Roflumilast ) for Sebhorreic Dermatitis
Overview Zoryve foam is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat people 9 years of age and older with seborrheic dermatitis. Zoryve foam is also …
FDA Approves Historic Roflumilast Foam 0.3% For Seborrheic Dermatitis
Dec 15, 2023 · Arcutis Biotherapeutics announced today the FDA approval of roflumilast foam 0.3% (ZORYVE) for the treatment of seborrheic dermatitis in patients aged 9 years and older. …
Seborrheic Dermatitis In two multicenter, randomized, double-blind, vehicle-controlled trials (Trial 203 and STRATUM), 683 adult and pediatric subjects 9 years of age or older with seborrheic …